Imunon(IMNN) - 2025 Q2 - Quarterly Results

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET Exhibit 99.1 LAWRENCEVILLE, N.J., August 5, 2025 – IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company ...